Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts.On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance ...